IMARC Group, a leading market research company, has released a report titled “Hyperlipidemia Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“. According to the report, The global hyperlipidemia drugs market size reached US$ 22.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 25.2 Billion by 2028, exhibiting a growth rate (CAGR) of 1.8% during 2023-2028.
Hyperlipidemia refers to a condition that causes abnormally high levels of fats or lipids in the blood. It is a common type of dyslipidemia that can be inherited or result from an unhealthy lifestyle and poor diet. The disorder may lead to cardiac stroke, peripheral vascular diseases, obesity, hypertension, and cardiovascular disorders(CVDs). Hyperlipidemia can be detected by performing a blood test called a lipid panel or lipid profile. Statins are the primary line of treatment in secondary hyperlipidemia caused by an unhealthy lifestyle. Some of the other common drugs used in the treatment of hyperlipidemia are bile acid sequestrants, PCSK9, and miscellaneous antihyperlipidemic agents, which help reduce the production of cholesterol in the liver. They also lower the number of lipids in the bloodstream and reduce inflammation and damage done to the cells.
Request Free Sample Report (Exclusive Offer on this report): https://www.imarcgroup.com/hyperlipidemia-drugs-market/requestsample
Hyperlipidemia Drugs Market Trends and Drivers:
The global hyperlipidemia drugs market is primarily driven by the increasing awareness regarding the associated risks of CVDs and high cholesterol. Governments are introducing new guidelines redefining at-risk patient groups and recommending the use of anti-hyperlipidemic to lower the risk of these diseases. In addition to this, the upcoming patent expiration has resulted in the genericization of statin and cholesterol absorption inhibitors, which is significantly augmenting the market growth. Furthermore, the launch of innovative products, such as the development of novel drugs, which offer improved efficacy and safety profile, is positively impacting the market across the globe. Moreover, there has been extensive research and development (R&D) activities for developing innovative drugs.
The report has segmented the market into the following categories:
Breakup by Drug Type:
- Bile Acid Sequestrants
- Cholesterol Absorption Inhibitors
- PCSK9 Inhibitors
Breakup by End User:
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Competitive Landscape with Key Player:
- Amgen Inc.
- AstraZeneca PLC
- Daiichi Sankyo Company Limited
- Eli Lilly and Company
- Esperion Therapeutics Inc.
- GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
- Immuron Limited
- Ionis Pharmaceuticals Inc.
- Merck & Co. Inc.
- Pfizer Inc.
- Sanofi S.A.
Ask Analyst for Free Sample Report: https://www.imarcgroup.com/request?type=report&id=2685&flag=F
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Email: [email protected]
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA
Follow us on Twitter: @imarcglobal